Novo Nordisk's Blockbuster Weight-Loss Drug Flops In Alzheimer's Trial
Novo Nordisk A/S (NYSE:NVO) stock fell on Monday after the company released topline results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease.
Benzinga ·